IMDX · Insight Molecular Diagnostics Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on IMDX. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About IMDX · Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Live Quote
HOLD (score +1) · 12-1 mom 70.4% · RSI 47.3 · above_both · -36.7% from high
Targets blend Wall Street consensus (3 analysts: low $4.00 / mean $8.33 / high $12.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Score falls well below the 45 threshold. Three anti-signal gates trigger: dilution risk from warrants and repeated capital raises, extreme concentration with Broadwood holding ~39%, and low liquidity that makes executing the only viable structure (income) impractical without severe slippage. The single concentrated buyer does not form a smart-money cluster, and the FDA catalyst remains too distant and unpriced for a recommendation-grade setup.
Score falls well below the 45 threshold. Three anti-signal gates trigger: dilution risk from warrants and repeated capital raises, extreme concentration with Broadwood holding ~39%, and low liquidity that makes executing the only viable structure (income) impractical without severe slippage. The single concentrated buyer does not form a smart-money cluster, and the FDA catalyst remains too distant and unpriced for a recommendation-grade setup.
Insight Molecular Diagnostics (Nasdaq: IMDX) is a pre-commercial precision diagnostics company centered on GraftAssure, a dd-cfDNA blood test for transplant rejection monitoring. The investigation triggered on Form 4 cluster activity — three June 11/15 filings turned out to be RSU vesting events (no-cost acquisitions at $0), not open-market purchases. However, a separate and more meaningful signal exists: Broadwood Partners LP, the company's largest shareholder (~39% of shares) and a board-connected entity, executed ~753k shares of open-market purchases in April 2026 alone across six trading days at weighted-average prices of $3.44–$3.88/share (~$2.7M total), followed by additional filings bringing their position to over 12.68M shares directly owned. The company submitted GraftAssureDx for FDA review on March 25, 2026 and expects UK CE marking via self-certification imminently in Q2 2026. Multiple peer-reviewed publications (American Journal of Transplantation, EFI, ERA, ATC) are creating data momentum heading into the American Transplant Congress in Boston June 20–24. The stock trades at $5.70 with a $184M market cap vs. analyst price targets of $8.33 (mean FV estimate) to $12 (upside scenario).